Go or no go? Sanofi’s Cablivi leads February’s approvals charge
Others in the FDA queue include Bausch’s psoriasis therapy Duobrii and Motif Bio’s antibiotic Iclaprim.
Upcoming events – Ascendis and Lilly hope for growth with pivotal data
Ascendis aims to hit the Heights, while Lilly hopes for success with Olumiant in eczema, a new indication for the troubled Jak inhibitor.
Upcoming events – Allergan and Lundbeck await depression and mania data
Allergan needs a win with rapastinel, while Lundbeck's chief exec faces her second clinical challenge.
Upcoming events – Allergy's long-awaited birch data and Caladrius's Treg test
Allergy Therapeutics awaits twice-delayed phase III data on its birch pollen project, while Caladrius Biosciences seeks validation of its Treg approach to type 1…
Upcoming events – Jazz and Macrogenics look to phase III readouts
Jazz wants to expand its sleep portfolio, while Macrogenics hopes trial data will support its first new drug application.
Upcoming events – pivotal data loom for Novavax and Mallinckrodt
Novavax awaits phase III data with its respiratory syncytial virus vaccine ResVax, while Mallinckrodt hopes to bounce back with its next big pipeline hope, CPP-1X plus…
Go or no go? Immunomedics, Exelixis and Alkermes await FDA letters
Shutdown or no, drug reviews are still under way, giving the sector something to look forward to as 2019 kicks off.
Upcoming events – Phase III readouts loom for Urogen and Mediwound
Urogen is gearing up to release the results of a pivotal trial of its lead asset – and so is Mediwound.
Upcoming events – Verona waits to exhale and a new test for Alexion
Verona Pharma needs another COPD win, while Alexion seeks a new use for its Soliris successor.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.